Overview
Metastatic squamous cell carcinoma to the lung, as a subset of non-small cell lung cancer (NSCLC), may present as oligometastatic disease 1. This state is characterized by a limited number of metastatic sites where definitive local therapy to all known disease may improve clinical outcomes 1.Diagnosis
Oligometastatic definition: Defined as five or fewer distinct extracranial metastatic sites 1.
Comprehensive staging: Identification of the primary tumor, regional nodal metastases, and all distant metastatic sites is required 1.
Feasibility assessment: Evaluation of whether all known disease sites can be safely and technically targeted with local therapy 1.Management
Multidisciplinary approach: Decision-making should involve a patient-centered, multidisciplinary team 1.
Definitive local therapy: Use of radiation, surgery, or other ablative methods to treat all known cancer sites (primary tumor, regional nodes, and metastases) with definitive intent 1.
Systemic therapy integration: Local therapies should be sequenced and integrated with systemic treatment regimens 1.
Management of progression: Local therapy may be utilized for specific scenarios of oligoprogression or recurrent disease 1.Key Recommendations
Use a patient-centered, multidisciplinary approach for all decision-making regarding the management of oligometastatic NSCLC 1. (Evidence: Strong)
Integrate definitive local therapy (radiation, surgery, or ablation) only when it is technically feasible and clinically safe to treat all known disease sites 1. (Evidence: Moderate)
Limit the application of comprehensive local consolidative therapy to patients with five or fewer distinct metastatic sites 1. (Evidence: Moderate)References
1 Iyengar P, All S, Berry MF, Boike TP, Bradfield L, Dingemans AC et al.. Treatment of Oligometastatic Non-Small Cell Lung Cancer: An ASTRO/ESTRO Clinical Practice Guideline. Practical radiation oncology 2023. link